Literature DB >> 31191178

Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.

Maureen A Mealy, Audra Boscoe, Jaime Caro, Michael Levy.   

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life.
METHODS: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms.
RESULTS: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score.
CONCLUSIONS: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.

Entities:  

Keywords:  EQ-5D; Multiple sclerosis (MS); Neuromyelitis optica spectrum disorder; Pain; Quality of life

Year:  2019        PMID: 31191178      PMCID: PMC6552992          DOI: 10.7224/1537-2073.2017-076

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  28 in total

1.  MS and neuromyelitis optica in Martinique (French West Indies).

Authors:  P Cabre; O Heinzlef; H Merle; G G Buisson; O Bera; R Bellance; J C Vernant; D Smadja
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

2.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica.

Authors:  J-B Chanson; H Zéphir; N Collongues; O Outteryck; F Blanc; M Fleury; P Vermersch; J de Seze
Journal:  Eur J Neurol       Date:  2010-11-18       Impact factor: 6.089

4.  The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

Authors:  Michelle Orme; John Kerrigan; David Tyas; Nicola Russell; Richard Nixon
Journal:  Value Health       Date:  2007 Jan-Feb       Impact factor: 5.725

5.  Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases.

Authors:  Y Kuroiwa; A Igata; K Itahara; S Koshijima; T Tsubaki
Journal:  Neurology       Date:  1975-09       Impact factor: 9.910

6.  Characteristics of Devic's disease (neuromyelitis optica) in Mexico.

Authors:  John Flores Rivera; John F Kurtzke; Vanessa J Alatriste Booth; Teresa Corona V
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

7.  Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies.

Authors:  J A Cabrera-Gómez; M Bonnan; A González-Quevedo; A Saiz-Hinarejos; R Marignier; S Olindo; F Graus; D Smadja; H Merle; L Thomas; A Gómez-García; P Cabre
Journal:  Mult Scler       Date:  2009-06-04       Impact factor: 6.312

8.  Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.

Authors:  Andrew McKeon; James P Fryer; Metha Apiwattanakul; Vanda A Lennon; Shannon R Hinson; Thomas J Kryzer; Claudia F Lucchinetti; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Sean J Pittock
Journal:  Arch Neurol       Date:  2009-09

9.  Do general and multiple sclerosis-specific quality of life instruments differ?

Authors:  Fraser Moore; Christina Wolfson; Lubo Alexandrov; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2004-02       Impact factor: 2.104

10.  Environmental changes and epidemiology of multiple sclerosis in the French West Indies.

Authors:  Philippe Cabre
Journal:  J Neurol Sci       Date:  2009-06-10       Impact factor: 3.181

View more
  10 in total

Review 1.  Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder.

Authors:  Maureen A Mealy; Sharon L Kozachik; Michael Levy
Journal:  Pain Manag Nurs       Date:  2019-05-15       Impact factor: 1.929

2.  Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.

Authors:  Maureen A Mealy; Sharon L Kozachik; Lawrence J Cook; Lauren Totonis; Ruth Andrea Salazar; Jerilyn K Allen; Marie T Nolan; Thomas J Smith; Michael Levy
Journal:  Neurology       Date:  2020-04-08       Impact factor: 9.910

3.  Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data.

Authors:  Carolyn E Schwartz; Roland B Stark; Brian D Stucky
Journal:  Qual Life Res       Date:  2020-12-02       Impact factor: 4.147

4.  Health utilities and costs for neuromyelitis optica spectrum disorder.

Authors:  Dyfrig A Hughes; Siobhan Bourke; Angela Jones; Rikesh Bhatt; Saif Huda; Kerry Mutch; Anu Jacob
Journal:  Orphanet J Rare Dis       Date:  2022-04-07       Impact factor: 4.123

5.  Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study.

Authors:  Martin W Hümmert; Louisa M Schöppe; Judith Bellmann-Strobl; Nadja Siebert; Friedemann Paul; Ankelien Duchow; Hannah Pellkofer; Tania Kümpfel; Joachim Havla; Sven Jarius; Brigitte Wildemann; Achim Berthele; Florian Then Bergh; Marc Pawlitzki; Luisa Klotz; Ingo Kleiter; Martin Stangel; Stefan Gingele; Martin S Weber; Juergen H Faiss; Refik Pul; Annette Walter; Uwe K Zettl; Makbule Senel; Jan-Patrick Stellmann; Vivien Häußler; Kerstin Hellwig; Ilya Ayzenberg; Orhan Aktas; Marius Ringelstein; Olivia Schreiber-Katz; Corinna Trebst
Journal:  Neurology       Date:  2022-01-26       Impact factor: 9.910

Review 6.  Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Authors:  Andrea Salazar-Camelo; Naveen George; Hesham Abboud; Sarah M Planchon; Marcelo Matiello; Maureen A Mealy; Andrew Goodman
Journal:  J Neurol       Date:  2021-09-05       Impact factor: 4.849

7.  The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.

Authors:  Xiaojun Li; Haoyou Xu; Min Zhao; Yuanqi Zhao; Zequan Zheng; Huiying Ouyang; Guixian Chen; Zhenzhen Lou; Haoxuan Chen; Jiahui Zhang; Yibo Zhan; Hui Mao; Changlin Zhang
Journal:  BMC Neurol       Date:  2022-08-19       Impact factor: 2.903

8.  The patient journey with NMOSD: From initial diagnosis to chronic condition.

Authors:  Guillermo Delgado-Garcia; Sheryl Lapidus; Rosa Talero; Michael Levy
Journal:  Front Neurol       Date:  2022-09-06       Impact factor: 4.086

9.  Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review.

Authors:  Ting Zhou; Haijing Guan; Luying Wang; Yao Zhang; Mingjun Rui; Aixia Ma
Journal:  Front Public Health       Date:  2021-06-29

Review 10.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.